Stock detail
Novavax (NVAX) stock price, chart, and key data
View Novavax stock price, chart movement, and headline metrics on Woodstock's stock detail page.

Stock detail
Novavax
NVAX · XNAS
$9.78
+5.16%
+$0.48
Key metrics
52-week range
$5.25 - $2.00
Close price
$9.30
Market cap
$1.5B
P/E ratio
-29.06
Beta
0.68
About the company
Novavax Inc
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.
Analyst rating summary
A current read on analyst sentiment from the insight feed.
Mean target
$13.25
2
Buy
/ 4
Recent calls
08/06/2026
Cantor Fitzgerald
Pete Stavropoulos
Buy · Price target $18.00
08/07/2026
Bank of America Securities
Alec Stranahan
Sell · Price target $7.00
08/04/2026
TD Cowen
Chris LoBianco
Hold · Price target $9.00
Ticker holders
Review politician disclosures and insider transactions in tabs.
No holder data is available for this category yet.
24/5 Trading
Act on the stock when the timing works for you.
With Woodstock, you can move from chart review to order placement in one flow. Trade eligible US stocks 24/5, even outside regular market hours.
*24-hour trading is available except during system maintenance. Some stocks are not eligible for extended-hours trading.
Download the app